Chemokine receptors in the pathogenesis and therapy of psoriasis

Journal of Dermatological Science

Volumn 65, Issue 1, 2012, Pages 4-11

  Mabuchi, Tomotaka ^a,b   Chang, Timothy W ^a   Quinter, Suzanne ^a   Hwang, Sam T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

T cells; CCR6; Chemokine receptors; IL22; Psoriasis

Indexed keywords

AN 2728; ANTIPSORIASIS AGENT; BETA DEFENSIN 2; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR6; CYTOKINE; JANUS KINASE INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY ABX IL8; PHOSPHODIESTERASE IV INHIBITOR; PONESIMOD; RUXOLITINIB; SCH 51125; SPHINGOSINE 1 PHOSPHATE 1 RECEPTOR ACTIVATOR; T 487; TOFACITINIB; UNCLASSIFIED DRUG;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GAMMA DELTA T LYMPHOCYTE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE MIGRATION; MOLECULAR INTERACTION; NAUSEA; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL MOVEMENT; CHEMOKINE CCL20; CYTOKINES; HUMANS; INTERLEUKINS; LIGANDS; LYMPHOCYTES; MICE; MODELS, BIOLOGICAL; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, CCR6; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; SKIN; TH17 CELLS;

EID: 84855198503     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.11.007     Document Type: Review

References (86)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001, 26:314-320.
2. Kawada A., Tezuka T., Nakamizo Y., Kimura H., Nakagawa H., Ohkido M., et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003, 31:59-64.
3. Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979, 301:555.
4. Griffiths C.E., Powles A.V., Leonard J.N., Fry L., Baker B.S., Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986, 293:731-732.
5. Clark R.A., Chong B., Mirchandani N., Brinster N.K., Yamanaka K., Dowgiert R.K., et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006, 176:4431-4439.
6. Suarez-Farinas M., Fuentes-Duculan J., Lowes M.A., Krueger J.G. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 2011, 131:391-400.
7. Homey B., Alenius H., Muller A., Soto H., Bowman E.P., Yuan W., et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002, 8:157-165.
8. Lonsdorf A.S., Hwang S.T., Enk A.H. Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol 2009, 129:2552-2566.
9. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
10. Bromley S.K., Mempel T.R., Luster A.D. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008, 9:970-980.
11. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
12. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
13. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
14. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
15. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
16. Fitch E., Harper E., Skorcheva I., Kurtz S.E., Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007, 9:461-467.
17. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
18. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
19. Johnson-Huang L.M., Suarez-Farinas M., Sullivan-Whalen M., Gilleaudeau P., Krueger J.G., Lowes M.A. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010, 130:2654-2663.
20. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
21. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72.
22. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203:2577-2587.
23. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
24. Hedrick M.N., Lonsdorf A.S., Shirakawa A.K., Lee C.R., Liao F., Singh S.P., et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009, 119:2317-2329.
25. Lim H.W., Lee J., Hillsamer P., Kim C.H. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol 2008, 180:122-129.
26. Liao F., Alderson R., Su J., Ullrich S.J., Kreider B.L., Farber J.M. STRL22 is a receptor for the CC chemokine MIP-3a. Biochem Biophys Res Commun 1997, 236:212-217.
27. Greaves D.R., Wang W., Dairaghi D.J., Dieu M.C., de Saint-Vis B., Franz-Bacon K., et al. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3a and is highly expressed human dendritic cells. J Exp Med 1997, 186:837-844.
28. Power C.A., Church D.J., Meyer A., Alouani S., Proudfoot A.E., Clark-Lewis I., et al. Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3α from lung dendritic cells. J Exp Med 1997, 186:825-835.
29. Homey B., Dieu-Nosjean M., Wiesenborn A., Massacrier C., Pin J., Oldham E., et al. Up-regulation of macrophage inflammatory protein-3a/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000, 164:6621-6632.
30. Fitzhugh D.J., Naik S., Caughman S.W., Hwang S.T. Cutting edge: CC chemokine receptor-6 (CCR6) is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro. J Immunol 2000, 165:6677-6681.
31. Nograles K.E., Davidovici B., Krueger J.G. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010, 29:3-9.
32. Hedrick M.N., Lonsdorf A.S., Hwang S.T., Farber J.M. CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 2010, 14:911-922.
33. Schutyser E., Struyf S., Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003, 14:409-426.
34. Yang D., Chertox O., Bykovskaia S.N., Chen Q., Buffo M.J., Shogan J., et al. β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528.
35. Grinlinton F.M., Skinner M.A., Birchall N.M., Tan P.L. γδ+ T cells from patients with psoriatic and rheumatoid arthritis respond to streptococcal antigen. J Rheumatol 1993, 20:982-987.
36. de Boer O.J., Verhagen C.E., Visser A., Bos J.D., Das P.K. Cellular interactions and adhesion molecules in psoriatic skin. Acta Derm Venereol Suppl (Stockh) 1994, 186:15-18.
37. Seung N.R., Park E.J., Kim C.W., Kim K.H., Kim K.J., Cho H.J., et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor γδ in plaque and guttate psoriasis. J Cutan Pathol 2007, 34:903-911.
38. Laggner U., Di Meglio P., Perera G.K., Hundhausen C., Lacy K.E., Ali N., et al. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2T cell subset with a potential role in psoriasis. J Immunol 2011, 187:2783-2793.
39. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
40. Gray E.E., Suzuki K., Cyster J.G. Cutting edge: identification of a motile IL-17-producing γδ T cell population in the dermis. J Immunol 2011, 186:6091-6095.
41. Girardi M., Lewis J., Glusac E., Filler R.B., Geng L., Hayday A.C., et al. Resident skin-specific γδ T cells provide local, nonredundant regulation of cutaneous inflammation. J Exp Med 2002, 195:855-867.
42. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol 2006, 126:25-31.
43. Mabuchi T., Takekoshi T., Hwang S.T. Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol 2011, 187:5026-5031.
44. Nestle F.O., Di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and disease. Nat Rev Immunol 2009, 9:679-691.
45. Dieu-Nosjean M.C., Massacrier C., Vanbervliet B., Fridman W.H., Caux C. IL-10 induces CCR6 expression during Langerhans cell development while IL-4 and IFN-γ suppress it. J Immunol 2001, 167:5594-5602.
46. Dieu-Nosjean M.C., Massacrier C., Homey B., Vanbervliet B., Pin J.J., Vicari A., et al. Macrophage inflammatory protein 3α is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000, 192:705-718.
47. Komine M., Karakawa M., Takekoshi T., Sakurai N., Minatani Y., Mitsui H., et al. Early inflammatory changes in the " perilesional skin" of psoriatic plaques: is there interaction between dendritic cells and keratinocytes?. J Invest Dermatol 2007, 127:1915-1922.
48. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S.L., Nussbaum R., et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005, 102:19057-19062.
49. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130.
50. Wang F., Lee E., Lowes M.A., Haider A.S., Fuentes-Duculan J., Abello M.V., et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol 2006, 126:1590-1599.
51. Vestergaard C., Just H., Baumgartner Nielsen J., Thestrup-Pedersen K., Deleuran M. Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm Venereol 2004, 84:353-358.
52. de Groot M., Teunissen M.B., Ortonne J.P., Lambert J.R., Naeyaert J.M., Picavet D.I., et al. Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res 2007, 299:305-313.
53. Goebeler M., Toksoy A., Spandau U., Engelhardt E., Brocker E.B., Gillitzer R. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998, 184:89-95.
54. Rottman J.B., Smith T.L., Ganley K.G., Kikuchi T., Krueger J.G. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin αEβ7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001, 81:335-347.
55. Wen H., Hogaboam C.M., Lukacs N.W., Cook D.N., Lira S.A., Kunkel S.L. The chemokine receptor CCR6 is an important component of the innate immune response. Eur J Immunol 2007, 37:2487-2498.
56. Jansen P.A., Rodijk-Olthuis D., Hollox E.J., Kamsteeg M., Tjabringa G.S., de Jongh G.J., et al. β-Defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009, 4:e4725.
57. Hollox E.J., Huffmeier U., Zeeuwen P.L., Palla R., Lascorz J., Rodijk-Olthuis D., et al. Psoriasis is associated with increased β-defensin genomic copy number. Nat Genet 2008, 40:23-25.
58. Chen S.C., de Groot M., Kinsley D., Laverty M., McClanahan T., Arreaza M., et al. Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 2010, 302:113-123.
59. Homey B., Meller S. Chemokines and other mediators as therapeutic targets in psoriasis vulgaris. Clin Dermatol 2008, 26:539-545.
60. Wells T.N., Power C.A., Shaw J.P., Proudfoot A.E. Chemokine blockers - therapeutics in the making?. Trends Pharmacol Sci 2006, 27:41-47.
61. desarg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 1986, 87:53-58.
62. 3 (tacalcitol). AAD Rev 1998, 138:63-70.
63. Raychaudhuri S.P., Jiang W.Y., Farber E.M., Schall T.J., Ruff M.R., Pert C.B. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999, 79:9-11.
64. Hirota K., Yoshitomi H., Hashimoto M., Maeda S., Teradaira S., Sugimoto N., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007, 204:2803-2812.
65. Carlsson J., Coleman R.G., Setola V., Irwin J.J., Fan H., Schlessinger A., et al. Ligand discovery from a dopamine D(3) receptor homology model and crystal structure. Nat Chem Biol 2011, 7:769-778.
66. Veldkamp C.T., Ziarek J.J., Peterson F.C., Chen Y., Volkman B.F. Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. J Am Chem Soc 2010, 132:7242-7243.
67. Yamaoka K., Tanaka Y. Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Nihon Rinsho Meneki Gakkai Kaishi 2009, 32:85-91.
68. Cohen S., Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010, 22:330-335.
69. Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.Q., Lal B.K., et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 1994, 91:6374-6378.
70. Harada D., Takada C., Nosaka Y., Takashima Y., Kobayashi K., Takaba K., et al. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol 2009, 9:55-62.
71. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-315.
72. Nazarian R., Weinberg J.M. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009, 10:1236-1242.
73. Baumer W., Hoppmann J., Rundfeldt C., Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007, 6:17-26.
74. Bolli M.H., Abele S., Binkert C., Bravo R., Buchmann S., Bur D., et al. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010, 53:4198-4211.
75. Giustizieri M.L., Mascia F., Frezzolini A., De Pita O., Chinni L.M., Giannetti A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immun 2001, 107:871-877.
76. Uchida T., Suto H., Ra C., Ogawa H., Kobata K., Okumura K. Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. Int Immunol 2002, 14:1431-1438.
77. Teraki Y., Miyake A., Takebayashi R., Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol 2004, 29:658-663.
78. Morita E., Kameyoshi Y., Hiragun T., Mihara S., Yamamoto S. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. Allergy 2001, 56:194-195.
79. Kakinuma T., Saeki H., Tsunemi Y., Fujita H., Asano N., Mitsui H., et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003, 111:592-597.
80. Campanati A., Goteri G., Simonetti O., Ganzetti G., Giuliodori K., Stramazzotti D., et al. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol 2007, 157:1155-1160.
81. Schulz B.S., Michel G., Wagner S., Suss R., Beetz A., Peter R.U., et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993, 151:4399-4406.
82. Kulke R., Bornscheuer E., Schluter C., Bartels J., Rowert J., Sticherling M., et al. The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 1998, 110:90-94.
83. Gillitzer R., Ritter U., Spandau U., Goebeler M., Brocker E.B. Differential expression of GRO-α and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996, 107:778-782.
84. Yamashita T., Akamatsu H., Tomitaka A., Ogawa Y., Sugawara N., Matsunaga K. IP-10 in atopic dermatitis. Allergy 2003, 58:261.
85. Oh S.T., Schramme A., Tilgen W., Gutwein P., Reichrath J. Overexpression of CXCL16 in lesional psoriatic skin. Dermatoendocrinology 2009, 1:114-118.
86. Fraticelli P., Sironi M., Bianchi G., D'Ambrosio D., Albanesi C., Stoppacciaro A., et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001, 107:1173-1181.